The current guidelines in the Netherlands (37) are in accordance with international guidelines (11, 13, 38, 39) and recommend that molecular testing for EGFR mutations and ALK rearrangements/fusions should be performed in patients with metastatic (non-squamous) NSCLC for whom curative treatment is no longer available. Here, EGFR is linked to non-small cell lung carcinoma.